Search

Your search keyword '"Behre, Gerhard"' showing total 539 results
Start Over Author "Behre, Gerhard"
539 results on '"Behre, Gerhard"'

9. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

Author

Schmidt, Volker, Niederwieser, Dietger, Schenk, Thomas, Behre, Gerhard, Klink, Anne, Pfrepper, Christian, Hinke, Axel, Beelen, Dietrich W., Junghanss, Christian, Uharek, Lutz, Krüger, William H., Hochhaus, Andreas, Sayer, Herbert G., and for the East German Study Group for Hematology and Oncology (OSHO)

Published
2018
Full Text
View/download PDF

11. Data from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 3 from PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia

Author

Bräuer-Hartmann, Daniela, primary, Hartmann, Jens-Uwe, primary, Wurm, Alexander Arthur, primary, Gerloff, Dennis, primary, Katzerke, Christiane, primary, Verga Falzacappa, Maria Vittoria, primary, Pelicci, Pier Giuseppe, primary, Müller-Tidow, Carsten, primary, Tenen, Daniel G., primary, Niederwieser, Dietger, primary, and Behre, Gerhard, primary

Published
2023
Full Text
View/download PDF

20. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, Ostermann, Helmut, Wolf, Hans-H., and Cornely, Oliver A.

Published
2017
Full Text
View/download PDF

21. Characterization of postvaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.

Author

Pfannes, Roald, Pierzchalski, Arkadiusz, Maddalon, Ambra, Simion, Alexandra, Zouboulis, Christos C., Behre, Gerhard, Zenclussen, Ana Claudia, Westphal, Sabine, Fest, Stefan, and Herberth, Gunda

Subjects
T cells, HEMATOLOGIC malignancies, COVID-19 vaccines, SARS-CoV-2, HEPATITIS B vaccines, CANCER vaccines, BCG vaccines
Abstract

Background: To evaluate the benefits of SARS-CoV-2 vaccination in cancer patients it is relevant to understand the adaptive immune response elicited after vaccination. Patients affected by hematologicmalignancies are frequently immune-compromised and show a decreased seroconversion rate compared to other cancer patients or controls. Therefore, vaccine-induced cellular immune responses in these patients might have an important protective role and need a detailed evaluation. Methods: Certain T cell subtypes (CD4, CD8, Tfh, γκT), including cell functionality as indicated by cytokine secretion (IFN, TNF) and expression of activation markers (CD69, CD154) were assessed via multi-parameter flow cytometry in hematologic malignancy patients (N=12) and healthy controls (N=12) after a second SARS-CoV-2 vaccine dose. The PBMC of post-vaccination samples were stimulated with a spike-peptide pool (S-Peptides) of SARS-CoV-2, with CD3/CD28, with a pool of peptides from the cytomegalovirus, Epstein-Barr virus and influenza A virus (CEF-Peptides) or left unstimulated. Furthermore, the concentration of spike-specific antibodies has been analyzed in patients. Results: Our results indicate that hematologic malignancy patients developed a robust cellular immune response to SARS-CoV-2 vaccination comparable to that of healthy controls, and for certain T cell subtypes even higher. The most reactive T cells to SARS-CoV-2 spike peptides belonged to the CD4 and Tfh cell compartment, being median (IQR), 3.39 (1.41-5.92) and 2.12 (0.55-4.14) as a percentage of IFN- and TNF-producing Tfh cells in patients. In this regard, the immunomodulatory treatment of patients before the vaccination period seems important as it was strongly associated with a higher percentage of activated CD4 and Tfh cells. SARS-CoV-2-and CEF-specific T cell responses significantly correlated with each other. Compared to lymphoma patients, myeloma patients had an increased percentage of SARS-CoV-2-specific Tfh cells. T-SNE analysis revealed higher frequencies of γκT cells in patients compared to controls, especially in myeloma patients. In general, after vaccination, SARS-CoV-2- specific T cells were also detectable in patients without seroconversion. Conclusion: Hematologic malignancy patients are capable of developing a SARS-CoV-2-specific CD4 and Tfh cellular immune response after vaccination, and certain immunomodulatory therapies in the period before vaccination might increase the antigen-specific immune response. A proper response to recall antigens (e.g., CEF-Peptides) reflects immune cellular functionality and might be predictive for generating a newly induced antigen-specific immune response as is expected after SARS-CoV-2 vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

Author

Pfrepper, Christian, Klink, Anne, Behre, Gerhard, Schenk, Thomas, Franke, Georg-Nikolaus, Jentzsch, Madlen, Schwind, Sebastian, Al-Ali, Haifa-Kathrin, Hochhaus, Andreas, Niederwieser, Dietger, and Sayer, Herbert Gottfried

Published
2016
Full Text
View/download PDF

29. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

Author

Chen, Peter, primary, Behre, Gerhard, additional, Hebert, Corey, additional, Kumar, Princy, additional, Farmer Macpherson, Lisa, additional, Graham-Clarke, Peita Louise, additional, De La Torre, Inmaculada, additional, Nichols, Russell M, additional, Hufford, Matthew M, additional, Patel, Dipak R, additional, and Naegeli, April N, additional

Published
2022
Full Text
View/download PDF

30. Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors

Author

Zjablovskaja, Polina, Kardosova, Miroslava, Danek, Petr, Angelisova, Pavla, Benoukraf, Touati, Wurm, Alexander A., Kalina, Tomas, Sian, Stephanie, Balastik, Martin, Delwel, Ruud, Brdicka, Tomas, Tenen, Daniel G., Behre, Gerhard, Fiore, Fréderic, Malissen, Bernard, Horejsi, Vaclav, and Alberich-Jorda, Meritxell

Published
2019
Full Text
View/download PDF

32. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

Author

Pönisch, Wolfram, Holzvogt, Bruno, Plötze, Madlen, Andrea, Marc, Bourgeois, Malvina, Heyn, Simone, Zehrfeld, Thomas, Hammerschmidt, Doreen, Schwarz, Maik, Edelmann, Thomas, Becker, Cornelia, Hoffmann, Franz Albert, Schwarzer, Andreas, Kreibich, Ute, Gutsche, Kerstin, Reifenrath, Kolja, Winkelmann, Cornelia, Krahl, Rainer, Remane, Yvonne, Hennig, Evelin, Schliwa, Thomas, Lindner, Tom, Kaiser, Thorsten, Vucinic, Vladan, Behre, Gerhard, and Niederwieser, Dietger

Published
2014
Full Text
View/download PDF

39. Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

Author

Vucinic, Vladan, Jentzsch, Madlen, Schwind, Sebastian, Bach, Enrica, Leiblein, Sabine, Remane, Yvonne, Rieprecht, Susanne, Otto, Sandra, Kubasch, Anne-Sophie, Behre, Gerhard, Cross, Michael, Platzbecker, Uwe, and Franke, Georg-Nikolaus

Subjects
CPX-351, induction therapy, Case Report, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, therapy-related acute myeloid leukemia, surgical procedures, operative, Oncology, hematopoeietic stem cell transplantation, hemic and lymphatic diseases, AML-MRC, ddc:610, CPX-351, AML-MRC, therapy-related acute myeloid leukemia, induction therapy, hematopoeietic stem cell transplantation, prognosis, prognosis
Abstract

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and treatment-related acute myeloid leukemia (tAML) after chemotherapy or radiation therapy for other neoplasms are associated with poor outcomes. CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine, has been shown to improve outcomes in AML-MRC and tAML compared with standard 7+3 regimens. Here we report the cases of four consecutive patients with AML-MRC or tAML who received CPX-351 as outpatient induction therapy immediately followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two patients received allo-HSCT in remission (one in complete remission and one in partial remission) and two patients received allo-HSCT in aplasia (one at 11 days and one at 52 days after the start of induction therapy with CPX-351). With a median follow-up of 188 days after allo-HSCT, all but one patient are alive and two are in remission. Further studies will help define and expand the role of CPX-351 in the treatment of AML-MRC and tAML, especially in patients expected to undergo allo-HSCT.

Published
2020

41. The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis

Author

Maiwald, Jan-Hendrik, primary, Sprung, Susanne, additional, Czapiewski, Piotr, additional, Lessel, Wiebke, additional, Scherping, Anna, additional, Schomburg, Dirk, additional, Plaumann, Markus, additional, Tomasik, Bartłomiej, additional, Behre, Gerhard, additional, Haybaeck, Johannes, additional, Ignatov, Atanas, additional, Eggemann, Holm, additional, and Nass, Norbert, additional

Published
2021
Full Text
View/download PDF

46. AML1-ETO downregulates the granulocytic differentiation factor C/EBP[alpha] in t(8;21) myeloid leukemia

Author

Pabst, Thomas, Mueller, Beatrice U., Harakawa, Nari, Schoch, Claudia, Haferlach, Torsten, Behre, Gerhard, Hiddemann, Wolfgang, Zhang, Dong-Er, and Tenen, Daniel G.

Abstract

The transcription factor CCAAT/enhancer binding protein [alpha], or C/EBP[alpha], encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBP[alpha] triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBP[alpha] protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBP[alpha] expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBP[alpha] in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBP[alpha] expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias., Author(s): Thomas Pabst [1]; Beatrice U. Mueller [1]; Nari Harakawa [1]; Claudia Schoch [2]; Torsten Haferlach [2]; Gerhard Behre [2]; Wolfgang Hiddemann [2]; Dong-Er Zhang [3]; Daniel G. Tenen (corresponding [...]

Published
2001
Full Text
View/download PDF

49. Comparison of non‐myeloablative and reduced‐intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes

Author

Jentzsch, Madlen, primary, Döhring, Christine, additional, Linke, Richard, additional, Hille, Andrea, additional, Grimm, Juliane, additional, Pönisch, Wolfram, additional, Vucinic, Vladan, additional, Franke, Georg‐Nikolaus, additional, Behre, Gerhard, additional, Niederwieser, Dietger, additional, and Schwind, Sebastian, additional

Published
2019
Full Text
View/download PDF

50. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1

Author

Pu Zhang, Behre, Gerhard, Jing Pan, Iwama, Atsushi, Wara-Aswapati, Nawarat, Radomska, Hanna S., Auron, Philip E., Tenen, Daniel G., and Zijie Sun

Subjects
Hematopoietic stem cells -- Research, Hematopoietic system -- Research, Leukemia research -- Analysis, Bone marrow cells -- Research, Science and technology
Abstract

The process through which multipotential hematopoietic cells commit to distinct lineages involves the induction of specific transcription factors. PU.1 (also known as Spi-1) and GATA-1 are transcription factors essential for the development of myeloid and erythroid lineages, respectively. Overexpression of PU.1 and GATA-1 can block differentiation in lineages in which they normally are down-regulated, indicating that not only positive but negative regulation of these factors plays a role in normal hematopoietic lineage development. Here we demonstrate that a region of the PU.1 Ets domain (the winged helix-turn-helix wing) interacts with the conserved carboxyl-terminal zinc finger of GATA-1 and GATA-2 and that GATA proteins inhibit PU.1 transactivation of critical myeloid target genes. We demonstrate further that GATA inhibits binding of PU.1 to c-Jun, a critical coactivator of PU.1 transactivation of myeloid promoters. Finally, PU.1 protein can inhibit both GATA-1 and GATA-2 transactivation function. Our results suggest that interactions between PU.1 and GATA proteins play a critical role in the decision of stem cells to commit to erythroid vs. myeloid lineages.

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results